**Core tip:** Diabetes mellitus (DM) may be associated with hepatocellular carcinoma (HCC) pathological features, old age and poor liver function, which may influence post-liver transplantation (LT) survival in hepatitis B virus (HBV)-related HCC patients. However, no direct relation between DM and HBV infection or HBV load were observed in HCC patients. The current data represent a multi-center study involving a larger number of samples, and suggest that DM may affect the long-term post-LT survival of HBV-related HCC patients, but not of tumor recurrence. Thus, HCC patients with DM undergoing LT should be closely followed to optimize outcomes. Follow-up examinations are especially important among DM patients who are elderly or who have the presence of vascular invasion and serum α-fetoprotein levels \> 2000 ng/mL pre-LT.

INTRODUCTION
============

Of the 350 million individuals infected with hepatitis B virus (HBV) worldwide, there are 130 million HBV carriers and 30 million chronically HBV-infected people in China\[[@B1],[@B2]\]. The incidence of hepatocellular carcinoma (HCC) in China is dramatically increased by HBV infection, which is the main cause of HCC\[[@B3],[@B4]\]. Over 70% of cases of HCC in China have been associated with HBV infection\[[@B5]\].

Diabetes mellitus (DM) is the sixth leading cause of death in China, and its prevalence in the adult Chinese population increased to 11.7% in 2010\[[@B6]\]. Recent studies have shown that DM may be a potential risk factor for HCC\[[@B5],[@B7],[@B8]\], and this hypothesis has been supported by several case control\[[@B9]-[@B12]\] and cohort studies\[[@B13]-[@B17]\]. Additionally, increased HCC prevalence in the diabetic population has been reported, possibly due to steatohepatitis\[[@B7],[@B9]\]. However, it is unknown whether HBV infection acts directly or additively with steatohepatitis on the incidence of HCC in DM patients. Liver transplantation (LT) has been established as the only curative method for simultaneous treatment of HCC and cirrhosis\[[@B18],[@B19]\], and is generally accepted as superior for early HCC with cirrhosis compared to hepatic resection\[[@B20],[@B21]\].

There has been recent debate about DM as an independent risk factor for post-treatment HCC recurrence and poor outcomes. Some studies have suggested that DM increases the risk of HCC recurrence and poor patient outcomes in patients undergoing hepatic resection\[[@B22]\]. However, other studies reported that DM does not worsen the prognosis of HCC patients after resection\[[@B23],[@B24]\]. Few studies have investigated the association between HBV, DM, tumor recurrence and long-term survival of HCC patients who underwent LT. The aim of this study was to investigate the potential associations between pre-existing DM with HBV-induced HCC, HCC recurrence and long-term survival after LT in a large cohort.

MATERIALS AND METHODS
=====================

Patient population
------------------

Between January 2000 and August 2013, 2128 patients were diagnosed with primary HCC and underwent LT at the General Hospital of Chinese People's Armed Police Force, Tianjin First Central Hospital and First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University (data from the China Liver Transplant Registry: https://[www.cltr.org/](www.cltr.org/)). Among the 2128 HCC patients who underwent LT, 1631 HBV-related cirrhosis patients with antiviral prophylaxis and complete follow-up information were studied retrospectively.

Inclusion criteria were: (1) adults ≥ 18-year-old; (2) fulfillment of the UCSF criteria\[[@B25]\] or Hangzhou criteria (China)\[[@B26]\]; (3) diagnosis of cirrhosis and HCC; and (4) diagnosis of pre-LT HBV infection. Exclusion criteria were: (1) pre-LT imaging diagnosis of HCC complicated by inferior vena cava tumor thrombus or extrahepatic tumor metastasis (including lymph node metastasis); (2) hepatitis C co-infection; (3) any history of alcohol abuse; and (4) HIV or HDV infection without adequate social support.

This study enrolled 1496 men and 135 women, with ages ranging between 25 and 80 years and a median age of 52.42 years. Of the 1631 patients, at the time of LT, 1336 (81.9%) were DM-negative and 295 (18.1%) had DM. Among the DM patients, 17 (5.8%) had type 1 diabetes and 278 (94.2%) had type 2 diabetes. Among the 295 DM cases, 29 (9.8%) were controlled by diet and exercise alone, 71 (24.1%) used oral sulfonylurea medications, 92 (31.2%) used oral sulfonylureas combined with insulin, and 103 (34.9%) used insulin alone. There were 101 (34.2%) patients with fasting blood glucose ≤ 7.0 mmol/L and 194 (65.8%) patients with fasting blood glucose \> 7.0 mmol/L, out of the total of 295 DM patients. The baseline characteristics of the 1631 HBV-induced HCC patients with or without DM are summarized in Table [1](#T1){ref-type="table"}.

###### 

Baseline characteristics of patients with diabetes mellitus and without diabetes mellitus *n* (%)

  **Category**                       **Diabetic (*n* = 295)**   **Non-diabetic (*n* = 1336)**   **Value**   **df**   ***P* value**
  ---------------------------------- -------------------------- ------------------------------- ----------- -------- ---------------
  Sex                                                                                           2.999       1        0.083
  Male                               278 (94.2)                 1218 (91.2)                                          
  Female                             17 (5.8)                   118 (8.8)                                            
  Age, yr                                                                                       23.690      1        0.000
  ≤ 50                               96 (32.5)                  643 (48.1)                                           
  \> 50                              199 (67.5)                 693 (51.9)                                           
  Tumor size                                                                                    4.333       3        0.228
  ≤ 3                                163 (55.3)                 704 (52.7)                                           
  3-5                                85 (28.8)                  350 (26.2)                                           
  5-7                                28 (9.5)                   157 (11.8)                                           
  \> 7                               19 (6.4)                   125 (9.4)                                            
  Number of tumor nodules                                                                       0.245       2        0.885
  Singer                             147 (49.8)                 666 (49.9)                                           
  ≥ 2, ≤ 3                           72 (24.4)                  341 (25.5)                                           
  ≥ 4                                76 (25.8)                  329 (24.6)                                           
  Venous invasion                                                                               0.641       1        0.423
  Absent                             256 (86.8)                 1135 (85.0)                                          
  Present                            39 (13.2)                  201 (15.0)                                           
  Lymph node invasion                                                                           1.272       1        0.304
  Absent                             284 (96.3)                 1265 (94.7)                                          
  Present                            11 (3.7)                   71 (5.3)                                             
  Capsular invasion                                                                             0.005       1        0.942
  Absent                             259 (87.8)                 1175 (87.9)                                          
  Present                            36 (12.2)                  161 (12.1)                                           
  Microsatellite lesions                                                                        0.430       1        0.512
  Absent                             234 (79.3)                 1082 (81.0)                                          
  Present                            61 (20.7)                  254 (19.0)                                           
  Edmondson                                                                                     4.359       2        0.108
  1                                  12 (4.1)                   27 (2.0)                                             
  2                                  168 (56.9)                 797 (59.7)                                           
  3 + 4 + 5                          115 (39.0)                 512 (38.3)                                           
  Serum AFP level, in ng/mL                                                                     5.518       4        0.236
  \< 200                             231 (78.3)                 966 (72.3)                                           
  200-400                            18 (6.1)                   87 (6.5)                                             
  400-1000                           17 (5.8)                   122 (9.1)                                            
  1000-2000                          13 (4.4)                   65 (4.9)                                             
  \> 2000                            16 (5.4)                   96 (7.2)                                             
  MELD score                                                                                    14.184      2        0.001
  \< 10                              97 (32.9)                  582 (43.6)                                           
  10-15                              94 (31.9)                  406 (30.4)                                           
  \> 15                              104 (35.3)                 348 (26.0)                                           
  Child-Pugh score                                                                              12.456      2        0.002
  A                                  125 (42.4)                 715 (53.5)                                           
  B                                  104 (35.3)                 396 (29.6)                                           
  C                                  66 (22.4)                  225 (16.8)                                           
  Fasting blood glucose, in mmol/L                                                              678.412     1        0.000
  \< 7                               101 (34.2)                 1273 (95.3)                                          
  ≥ 7                                194 (65.8)                 63 (4.7)                                             
  BMI, in kg/m^2^                                                                               7.937       3        0.047
  \< 18.5                            19 (6.4)                   69 (5.2)                                             
  18.5-24                            164 (55.6)                 856 (64.1)                                           
  24-28                              84 (28.5)                  295 (22.1)                                           
  \> 28                              28 (9.5)                   116 (8.7)                                            
  ALP, in IU/L                                                                                  1.546       1        0.214
  ≤ 112                              179 (60.7)                 862 (64.5)                                           
  \> 112                             116 (39.3)                 474 (35.5)                                           
  GGT, in IU/L                                                                                  2.196       1        0.138
  ≤ 54                               107 (36.3)                 547 (40.9)                                           
  \> 54                              188 (63.7)                 789 (59.1)                                           
  AST, in IU/L                                                                                  2.682       2        0.262
  ≤ 40                               102 (34.6)                 481 (36.0)                                           
  40-80                              107 (36.3)                 526 (39.4)                                           
  \> 80                              86 (29.2)                  329 (24.6)                                           
  ALT, in IU/L                                                                                  3.142       2        0.208
  ≤ 40                               121 (41.0)                 566 (42.4)                                           
  40-80                              105 (35.6)                 517 (38.7)                                           
  \> 80                              69 (23.4)                  253 (18.9)                                           
  TC, in mmol/L                                                                                 22.536      1        0.000
  ≤ 1.7                              250 (84.7)                 1245 (93.2)                                          
  \> 1.7                             45 (15.3)                  91 (6.8)                                             
  CH, in mmol/L                                                                                 3.840       2        0.147
  \< 3.88                            185 (62.7)                 865 (64.7)                                           
  3.88-5.2                           67 (22.7)                  329 (24.6)                                           
  \> 5.2                             43 (14.6)                  142 (10.6)                                           
  Pre-LT antitumor therapy                                                                      0.451       2        0.798
  No                                 219 (74.5)                 1016 (76.2)                                          
  local therapy                      48 (16.3)                  209 (15.7)                                           
  Resection                          27 (9.2)                   109 (8.2)                                            
  HBeAg                                                                                         0.670       1        0.413
  Negative                           232 (78.6)                 1021 (76.4)                                          
  Positive                           63 (21.4)                  315 (23.6)                                           
  HBV DNA, in IU/mL                                                                             6.140       1        0.013
  Negative, ≤ 10^3^                  191 (64.7)                 760 (56.9)                                           
  Positive, ≥ 10^3^                  104 (35.3)                 576 (43.1)                                           
  Post-LT HBV recurrence                                                                        0.217       1        0.740
  No                                 285 (96.6)                 1283 (96.0)                                          
  Yes                                10 (3.4)                   53 (4.0)                                             

BMI: Body mass index; DM: Diabetes mellitus; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transpeptidase; TG: Triglyceride; CH: Cholesterol; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; LT: Liver transplantation.

HBV infection diagnosis and treatment
-------------------------------------

For HBV-related patients, the pre-LT HBV infection status was checked routinely using the following viral markers: hepatitis B surface antigen (HBsAg); HB surface antibody (HBsAb), HB e antigen (HBeAg); hepatitis B core antibody (HBcAb); and HBV deoxyribonucleic acid (DNA) levels. HBV infection was defined by the presence of serum HBsAg or HBV DNA positivity. Before and after LT, HBV status was assessed using HBV markers and PCR for HBV DNA. In order to identify lamivudine resistance, viral mutation tests were also conducted\[[@B27]\]. Percutaneous or transjugular liver biopsies were performed to prove HBV re-infection. HBV genotyping was not performed in the majority of patients, and, therefore, was not included in the final analysis. All patients were routinely given nucleoside analogues (lamivudine, adefovir or entecavir) pre- and post-LT, and hepatitis B immunoglobulins post-LT (Table [2](#T2){ref-type="table"}).

###### 

Antiviral prophylaxis before and after liver transplantation for hepatitis B virus reinfection

  **Patients with high risk of HBV reinfection** **\[HBV-DNA ≥ 10^5^ copies/mL or HBeAg(+)\]**                                                                                 **Patients with low risk of HBV reinfection** **\[HBV-DNA \< 10^5^ copies/mL or HBeAg(-)\]**
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pre-LT: nucleoside analogues, qd 2-4 w                                                                                                                                       Pre-LT: nucleoside analogues, qd 0-2 w
  Intraoperative: HBIG 4000 IU, iv                                                                                                                                             Intraoperative: HBIG 2000 IU, iv
  Post-LT: HBIG 1000 IU, iv, qd, 1-7 d                                                                                                                                         Post-LT: HBIG 1000 IU, iv, qd, 1-7d
  After 7 d, HBIG 1000 IU, iv, once a week; or HBIG 400 IU, im, qd or qod or twice a week. Adjust frequency of HBIG administration to reach target therapeutic concentration   After 7 d, HBIG 1000 IU, iv, once a week; or HBIG 400 IU, im, qd or qod or twice a week. Adjust frequency of HBIG administration to reach target therapeutic concentration
  Target therapeutic concentration post-LT                                                                                                                                     Target therapeutic concentration post-LT
  ≤ 6 mo post-LT: anti-HBs titer ≥ 500 IU/L                                                                                                                                    ≤ 6 mo post-LT: anti-HBs titer ≥ 300 IU/L
  6-12 mo post-LT: anti-HBs titer ≥ 200 IU/L                                                                                                                                   6-12 mo post-LT: anti-HBs titer ≥ 200 IU/L
  ≥ 12 mo post-LT: anti-HBs titer ≥ 100 IU/L                                                                                                                                   ≥ 12 mo post-LT: anti-HBs titer ≥ 100 IU/L

HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; LT: Liver transplantation.

HCC and tumor recurrence assessment
-----------------------------------

Pre-LT HCC diagnosis was confirmed by a combination of two abdominal imaging techniques \[ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI)\], and by measuring serum α-fetoprotein (AFP) levels, or positron emission tomography (PET), if necessary, to exclude extrahepatic tumor metastasis. HCC and cirrhosis were diagnosed by pathological examination post- LT.

During the LT follow-up, routine examinations included X-ray imaging, abdominal ultrasonography, whole-body CT scans and measurement of serial serum AFP levels. Early tumor recurrence or metastasis was assessed by monthly monitoring of AFP levels and abdominal ultrasonography, and by whole-body CT, MRI examinations and bone scintigraphy every 3 to 6 mo. Histological confirmation of recurrence was conducted using patient biopsies, if necessary. Liver function tests were regularly checked before and after LT.

DM assessment and post-LT treatment
-----------------------------------

Pre-LT DM status was determined by retrospective review and laboratory tests, and assessed using the DM history. Medical history included medical records, recent history and physical examination records of use of oral hypoglycemic agents or insulin. Patients were also asked if they had a history of physician-diagnosed DM. The diagnostic criteria for DM consisted of fasting (≥ 8 h) plasma glucose levels ≥ 126 mg/dL and 2-h oral glucose tolerance test results showing ≥ 200 mg/dL\[[@B28]\]. Post-LT DM status was not included in this study. The treatment method for early post-LT DM was mainly insulin alone or oral sulfonylureas combined with insulin, according to fasting plasma glucose levels and 2-h oral glucose tolerance test results.

Study variables
---------------

Variables analyzed included sex, age, body mass index (BMI), DM, HBV markers, pathologic tumor characteristics (including number of tumor nodules, tumor size, venous invasion, lymph node invasion, capsular invasion and microsatellite lesions), serum AFP levels, Child-Pugh scores, model for end-stage liver disease (MELD) scores, and alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), triglyceride (TG), and cholesterol (CH) levels. Pre-LT antitumor therapy and post LT follow-up data included post-LT HBsAg reinfection, tumor recurrence, metastasis and survival time. These variables were collected and recorded in the databases of the China Liver Transplant Registry (https://[www.cltr.org/](www.cltr.org/)).

Patient height and weight were recorded prior to LT, as well as BMI for all patients. BMI was defined as weight in kilograms divided by height^2^ (m^2^). All included patients tested positive for HBsAg and showed detectable HBV DNA levels within the 3 mo prior to LT. Liver function levels and blood fat levels were measured at the time of transplant. The tumor nodule number, tumor nodule size (maximum diameter), vascular invasion, perihepatic lymph node invasion, capsular invasion, microsatellite lesions and tumor differentiation were determined by experienced pathologists.

Statistical analysis
--------------------

Categorical variables and non-normal distribution quantitative data were analyzed to compare the differences between non-diabetic and diabetic groups using χ^2^ tests and Mann-Whitney tests, respectively. From the date of LT to the date of death or to the most recent follow-up, survival time was calculated. The Kaplan-Meier method was used to analyze overall and recurrence-free survival. The log-rank test (Mantel-Cox) was used to compare group survival curves. Additionally, multivariate step-wise Cox regression was performed to analyze survival and tumor recurrence risk factors among LT patients. Statistical calculations were carried out using SPSS 17.0 software (SPSS Inc., Chicago, IL, United States). Two-sided *P* of \< 0.05 was considered statistically significant.

RESULTS
=======

Baseline characteristic comparisons between HBV-HCC patients with or without DM
-------------------------------------------------------------------------------

The mean ages in patients with or without DM were 54.1 or 50.8, respectively (*t* = 6.597, *P* \< 0.001). Mean patient BMI with or without DM was 24.2 for both (*t* = 0.036, *P* = 0.971). Mean fasting plasma glucose levels were 9.23 in DM patients, and 5.20 in non-DM patients (*t* = 16.849, *P* \< 0.001). The mean TC level (*t* = 2.342, *P* = 0.019) and CH level (*t* = 1.106, *P* = 0.269) were 1.12 or 4.46 in DM patients and 0.92 or 3.82 in non-DM patients, respectively.

In the current study, patients with DM exhibited a higher proportion of individuals with age \> 50-years-old (67.5% *vs* 51.9%, χ^2^ = 23.690, *P* \< 0.001), Child-Pugh grade B (35.3% *vs* 29.6%, χ^2^ = 13.456, *P* = 0.002) and C (22.4% *vs* 16.8%, χ^2^ = 13.456, *P* = 0.002), MELD scores \> 15 (35.3% *vs* 26.0%, χ^2^ = 14.184, *P* = 0.001), BMI of 24-28 (28.5% *vs* 22.1%, χ^2^ = 7.937, *P* = 0.047), TC \> 1.7 mmol/L (15.3% *vs* 6.8%, χ^2^ = 22.536, *P* \< 0.001) and HBV DNA ≤ 10^3^ IU/mL (64.7% *vs* 56.9%, χ^2^ = 6.140, *P* = 0.013), when compared with non-DM patients (Table [1](#T1){ref-type="table"}).

Analysis of DM and non-DM patients showed significant differences in age (*P* \< 0.001), MELD scores (*P* = 0.001), Child-Pugh grade (*P* = 0.002), BMI (*P* = 0.047), TC levels (*P* \< 0.001) and HBV DNA (*P* = 0.013; Table [1](#T1){ref-type="table"}). No significant differences were observed between patients with and without DM for other factors analyzed (Table [1](#T1){ref-type="table"}).

Overall survival and tumor recurrence comparisons by univariate analysis between HBV-HCC patients with or without DM
--------------------------------------------------------------------------------------------------------------------

Complete follow-up monitoring of the 1631 HBV-associated HCC patients who underwent LT was conducted. The median survival time was 62.0 ± 39.1 mo (0 to 152 mo) in DM patients and 67.0 ± 38.9 mo (0 to 165 mo) in non-DM patients. Univariate analysis of 1631 patients showed that 1-, 3- and 5-year overall survival rates post-LT were 79%, 73% and 71% in DM patients, respectively, and 84%, 78% and 76% in non-DM patients, respectively. Overall survival rates post-LT were significantly different between the HCC patients with DM and those without DM (*P* = 0.041; Figure [1A](#F1){ref-type="fig"}).

![Overall (A) and recurrence-free (B) survival rates of diabetes mellitus and non-diabetes mellitus patients with hepatocellular carcinoma. DM: Diabetes mellitus.](WJG-22-9571-g001){#F1}

The median tumor recurrence-free survival time was 55.0 ± 40.9 mo in DM patients and 62.0 ± 41.3 mo (0 to 165 mo) in non-DM patients. Univariate analysis of 1631 patients found that post-LT 1-, 3- and 5-year recurrence-free survival rates were 73%, 69% and 67% in DM patients, respectively, and 77%, 72% and 70% in non-DM patients, respectively. However, there were no significant differences in tumor recurrence-free survival rates between the two groups (*P* = 0.096; Figure [1B](#F1){ref-type="fig"}).

Risk factors for overall survival and recurrence-free survival comparisons by univariate analysis between HBV-HCC patients with or without DM
---------------------------------------------------------------------------------------------------------------------------------------------

Table [3](#T3){ref-type="table"} shows the results of a stratified analysis of risk factors for overall survival of HBV-related HCC patients with and without DM. Significant survival differences were found between DM and non-DM patients in relation to age \> 50 years (*P* = 0.002; Figure [2A](#F2){ref-type="fig"}), tumor size ≤ 3 cm (*P* = 0.047), number of tumor nodules between two and three (*P* = 0.007), vascular invasion (*P* = 0.033; Figure [2B](#F2){ref-type="fig"}), Child-Pugh grade B (*P* = 0.018), BMI of 18.5-24 (*P* = 0.048), ALT levels of 40-80 IU/L (*P* = 0.017; Figure [2C](#F2){ref-type="fig"}), AST levels of 40-80 IU/L (*P* = 0.038), TC levels ≤ 1.7 mmol/L (*P* = 0.021), no pre-LT antitumor therapy (*P* = 0.020), and absence of post-LT HBsAg reinfection (*P* = 0.045). When compared with non-DM patients, DM patients with these factors had poorer overall 1-, 3- and 5-year post-LT survival rates. Analysis of patients with vascular invasion showed that the 1-, 3- and 5-year post-LT survival rates were 45%, 28% and 25% in DM patients, respectively, compared to 63%, 47% and 42% in non-DM patients, respectively. DM patients \> 50 years of age had 1-, 3- and 5-year post-LT survival rates of 79%, 73% and 71%, respectively, compared to 88%, 83% and 80% in non-DM patients, respectively. DM patients with ALT levels of 40 to 80 IU/L had overall 1-, 3- and 5-year post-LT survival rates of 76%, 71% and 70%, respectively, compared to 85%, 78% and 76% in non-DM patients, respectively.

![Overall survival rates of diabetes mellitus and non-diabetes mellitus hepatocellular carcinoma patients with presence of vascular invasion (A), age \> 50 years (B), alanine aminotransferase levels \> 40, ≤ 80 IU/L (C). ALT: Alanine aminotransferase; DM: Diabetes mellitus.](WJG-22-9571-g002){#F2}

###### 

Univariate analysis of overall 1-, 3- and 5-year survival rates post-liver transplantation between patients with diabetes mellitus and without diabetes mellitus

  **Variables**                      **DM, %**   **Non-DM, %**   ***P* value**                     
  ---------------------------------- ----------- --------------- --------------- ----- ----- ----- -------
  Sex                                                                                              
  Male                               80          74              72              84    77    75    0.140
  Female                             76          62              62              90    88    86    0.016
  Age, yr                                                                                          
  ≤ 50                               80          73              73              80    74    71    0.970
  \> 50                              79          73              71              88    83    80    0.002
  Tumor size, in cm                                                                                
  ≤ 3                                83          79              79              90    86    83    0.047
  3-5                                86          79              74              87    79    77    0.689
  5-7                                66          49              43              71    65    63    0.171
  \> 7                               36          30              30              63    49    48    0.055
  Number of tumor nodules                                                                          
  Single                             85          82              79              90    84    82    0.325
  2-3                                73          68              68              86    81    79    0.007
  ≥ 4                                76          62              60              72    64    61    0.961
  Venous invasion                                                                                  
  Absent                             85          80              79              88    84    82    0.113
  Present                            45          28              25              63    47    42    0.033
  Lymph node invasion                                                                              
  Absent                             80          74              72              85    79    76    0.032
  Present                            73          64              64              78    70    66    0.979
  Capsular invasion                                                                                
  Absent                             80          74              72              85    79    77    0.050
  Present                            75          61              61              79    72    70    0.554
  Edmondson                                                                                        
  1                                  91          91              91              100   100   100   0.134
  2                                  82          77              75              87    81    78    0.124
  3 + 4 + 5                          74          66              64              79    73    71    0.229
  Serum AFP level, in ng/mL                                                                        
  \< 200                             85          81              79              88    83    82    0.161
  200-400                            64          64              64              78    68    66    0.502
  400-1000                           71          51              42              82    72    66    0.189
  1000-2000                          68          41              41              73    61    55    0.454
  \> 2000                            34          26              26              62    56    51    0.052
  MELD score                                                                                       
  \< 10                              79          68              68              84    77    74    0.101
  10-15                              78          70              70              84    78    76    0.197
  \> 15                              82          80              75              85    80    78    0.423
  Child-Pugh class                                                                                 
  A (5-6)                            83          78              78              85    79    76    0.792
  B (7-9)                            75          67              63              83    78    75    0.018
  C (≥ 9)                            79          74              72              82    77    75    0.479
  Fasting blood glucose, in mmol/L                                                                 
  ≤ 7                                77          73              71              85    79    76    0.145
  \> 7                               80          73              71              80    73    67    0.955
  BMI, in kg/m^2^                                                                                  
  \< 18.5                            68          62              62              81    79    76    0.156
  18.5-24                            77          72              70              84    78    76    0.048
  24-28                              86          78              76              85    79    76    0.951
  \> 28                              81          72              72              85    80    74    0.656
  ALP                                                                                              
  ≤ 112                              83          78              76              87    81    78    0.281
  \> 112                             74          66              65              80    74    72    0.102
  GGT                                                                                              
  ≤ 54                               87          86              85              92    88    85    0.559
  \> 54                              75          66              63              79    72    69    0.104
  ALT, in IU/L                                                                                     
  ≤ 40                               86          81              80              89    85    83    0.339
  40-80                              73          68              65              83    77    74    0.017
  \> 80                              77          68              66              75    68    64    0.633
  AST, in IU/L                                                                                     
  ≤ 40                               88          82              80              91    86    84    0.307
  40-80                              76          71              70              85    78    76    0.038
  \> 80                              74          67              64              74    68    64    0.872
  TC, in mmol/L                                                                                    
  ≤ 1.7                              79          72              71              85    79    77    0.021
  \> 1.7                             82          79              76              79    71    64    0.473
  CH, in mmol/L                                                                                    
  ≤ 3.88                             81          75              73              85    80    77    0.151
  3.88-5.2                           74          69              67              86    78    75    0.058
  \> 5.2                             83          71              71              77    71    68    0.737
  Pre-LT antitumor therapy                                                                         
  No                                 77          73              71              85    79    76    0.020
  local therapy                      83          71              71              79    73    71    0.910
  Resection                          92          80              72              88    84    80    0.809
  HBeAg                                                                                            
  Negative                           79          73              71              85    78    76    0.055
  Positive                           82          75              73              83    79    76    0.446
  HBV-DNA, in × 10^3^ U/mL                                                                         
  \< 1                               80          73              71              85    79    78    0.072
  \> 1                               77          73              72              84    77    74    0.236
  Post-LT HBsAg reinfection                                                                        
  Negative                           79          73              72              84    79    76    0.045
  Positive                           80          70              60              87    73    69    0.678

BMI: Body mass index; DM: Diabetes mellitus; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transpeptidase; TG: Triglyceride; CH: Cholesterol; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; LT: Liver transplantation.

Additionally, a trend was observed in survival differences between DM and non-DM patients in relation to tumor size \> 7 cm (*P* = 0.055), no capsular invasion (*P* = 0.050), serum AFP levels \> 2000 ng/mL (*P* = 0.052) and HBeAg negativity (*P* = 0.055).

Stratified analysis of risk factors for the tumor recurrence-free survival between DM and non-DM patients (Table [4](#T4){ref-type="table"}) showed that age \> 50 years (*P* = 0.015; Figure [3A](#F3){ref-type="fig"}), two to three tumor nodules (*P* = 0.031), presence of vascular invasion (*P* = 0.005; Figure [3B](#F3){ref-type="fig"}), presence of microsatellite lesions (*P* = 0.039) and ALT levels of 40-80 IU/L (*P* = 0.033; Figure [3C](#F3){ref-type="fig"}) were associated with significant tumor recurrence-free survival differences. DM patients with these factors had poorer 1-, 3- and 5-year recurrence-free survival rates post-LT when compared with non-DM patients (Table [4](#T4){ref-type="table"}). Analysis of the presence of vascular invasion in DM patients found that 1-, 3- and 5-year recurrence-free post-LT survival rates were 28%, 22% and 19%, respectively, but 48%, 37% and 35% in non-DM patients, respectively. DM patients \> 50 years of age had 1-, 3- and 5-year post-LT survival rates of 73%, 69% and 66%, respectively, while non-DM patients had post-LT survival rates of 81%, 75% and 73%, respectively. DM patients with ALT levels between 40 and 80 IU/L had 1-, 3- and 5-year post-LT survival rates of 68%, 63% and 60%, respectively, compared to post-LT survival rates of 77%, 70% and 68% in non-DM patients, respectively.

![Recurrence-free survival rates of diabetes mellitus and non-diabetes mellitus hepatocellular carcinoma patients with vascular invasion and (A), age \> 50 years (B), alanine aminotransferase levels between 40 and 80 IU/L (C). ALT: Alanine aminotransferase; DM: Diabetes mellitus.](WJG-22-9571-g003){#F3}

###### 

Univariate analysis of tumor recurrence-free 1-, 3- and 5-year survival rates post-liver transplantation between patients with diabetes mellitus and without diabetes mellitus

  **Variables**                      **DM, %**   **Non-DM, %**   ***P* value**                     
  ---------------------------------- ----------- --------------- --------------- ----- ----- ----- -------
  Sex                                                                                              
  Male                               73          69              67              77    71    69    0.204
  Female                             76          63              63              83    82    80    0.110
  Age, yr                                                                                          
  ≤ 50                               73          68              68              73    69    67    0.940
  \> 50                              73          69              66              81    75    73    0.015
  Tumor size, in cm                                                                                
  ≤ 3                                78          75              75              85    81    79    0.076
  3-5                                82          75              71              80    73    71    0.823
  5-7                                52          43              31              58    54    53    0.174
  \> 7                               31          25              25              47    39    39    0.087
  Number of tumor nodules                                                                          
  Single                             81          77              75              83    79    77    0.475
  2-3                                67          64              64              79    75    73    0.031
  ≥ 4                                64          57              55              63    55    53    0.825
  Venous invasion                                                                                  
  Absent                             80          76              74              82    78    76    0.301
  Present                            28          22              19              48    37    35    0.005
  Lymph node invasion                                                                              
  Absent                             74          69              67              78    73    71    0.058
  Present                            64          64              64              67    59    55    0.580
  Capsular invasion                                                                                
  Absent                             75          71              69              78    73    71    0.201
  Present                            60          55              55              69    67    62    0.192
  Microsatellite lesions                                                                           
  Absent                             79          74              72              80    75    73    0.542
  Present                            52          49              46              63    60    58    0.039
  Edmonton                                                                                         
  1                                  91          91              91              100   100   100   0.134
  2                                  77          73              72              80    74    72    0.375
  3 + 4 + 5                          67          59              57              72    67    66    0.175
  Serum AFP level, in ng/mL                                                                        
  \< 200                             80          76              75              82    78    76    0.272
  200-400                            59          59              59              72    63    62    0.484
  400-1000                           65          46              37              77    65    63    0.251
  1000-2000                          61          43              43              62    55    49    0.682
  \> 2000                            17          17              17              44    42    39    0.055
  MELD score                                                                                       
  \< 10                              68          60              58              75    69    67    0.058
  10-15                              72          70              70              78    73    70    0.412
  \> 15                              79          76              72              79    76    74    0.534
  Child-Pugh class                                                                                 
  A                                  75          71              69              78    72    70    0.672
  B                                  69          65              61              77    72    70    0.052
  C                                  76          71              71              76    73    71    0.610
  Fasting blood glucose, in mmol/L                                                                 
  ≤ 7                                72          68              67              77    72    70    0.154
  \> 7                               74          69              67              70    68    63    0.914
  BMI, in kg/m^2^                                                                                  
  \< 18.5                            63          57              57              80    72    69    0.223
  18.5-24                            73          70              68              77    72    70    0.216
  24-28                              76          69              69              78    73    71    0.524
  \> 28                              77          69              63              76    71    67    0.774
  ALP, in IU/L                                                                                     
  ≤ 112                              80          75              73              81    75    73    0.747
  \> 112                             63          60              57              71    67    65    0.056
  GGT, in IU/L                                                                                     
  ≤ 54                               85          84              82              87    82    80    0.957
  \> 54                              67          60              58              70    65    63    0.101
  AST, in IU/L                                                                                     
  ≤ 40                               81          76              73              84    79    78    0.201
  40-80                              69          65              65              78    72    70    0.103
  \> 80                              70          65              62              66    61    58    0.767
  ALT, in IU/L                                                                                     
  ≤ 40                               79          76              75              82    79    77    0.318
  40-80                              68          63              60              77    70    68    0.033
  \> 80                              72          65              64              65    60    58    0.376
  TC, in mmol/L                                                                                    
  ≤ 1.7                              74          69              67              78    73    71    0.113
  \> 1.7                             71          68              65              66    63    60    0.894
  CH, in mmol/L                                                                                    
  \< 3.88                            75          70              68              78    74    72    0.175
  3.88-5.2                           68          66              64              79    72    71    0.092
  \> 5.2                             76          68              68              66    60    57    0.415
  Pre-LT antitumor therapy                                                                         
  No                                 73          68              67              78    72    70    0.061
  local therapy                      68          66              66              70    67    64    0.939
  Resection                          81          77              70              83    79    76    0.758
  HBeAg                                                                                            
  Negative                           72          69              66              78    71    70    0.095
  Positive                           77          69              69              75    74    71    0.633
  HBV-DNA, in × 10^3^ IU/mL                                                                        
  \< 1                               75          69              68              78    74    72    0.165
  \> 1                               71          68              65              76    70    67    0.256
  Post-LT HBsAg reinfection                                                                        
  Negative                           73          69              67              77    73    70    0.092
  Positive                           70          60              60              72    60    58    0.899

BMI: Body mass index; DM: Diabetes mellitus; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transpeptidase; TG: Triglyceride; CH: Cholesterol; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; LT: Liver transplantation.

Trends were observed in tumor recurrence-free survival differences between DM and non-DM patients with AFP levels \> 2000 ng/mL (*P* = 0.055) and with AST levels \>112 IU/L (*P* = 0.056).

Risk factors for overall survival and tumor recurrence comparisons by multivariate analysis between HBV-HCC patients with or without DM
---------------------------------------------------------------------------------------------------------------------------------------

The multivariate Cox modeling for overall survival included sex, age, BMI, DM, number of tumor nodules, tumor size, venous invasion, lymph node invasion, capsular invasion, microsatellite lesions, Edmondson grade, AFP level, Child-Pugh score, MELD score, ALP, GGT, AST ALT, TC, CH, HBeAg, HBV DNA, pre-LT antitumor therapy and post-LT HBsAg reinfection. Multivariate analysis (Table [5](#T5){ref-type="table"}) revealed that DM \[hazard rate (HR) = 1.591; 95% confidence interval (CI): 1.239-2.041, *P* \< 0.001\] was an independent predictor of poor survival, and that age (HR = 0.781, *P* = 0.017), vascular invasion (*P* \< 0.001), number of tumor nodules ≥ 2 (HR = 1.695-2.342, *P* \< 0.001), tumor size \> 5 cm (HR = 2.093-3.496, *P* \< 0.00), AFP level pre-LT \> 1000 ng/mL (HR = 1.860-2.065, *P* ≤ 0.001), ALT level \> 40 IU/L (HR = 1.103-1.246, *P* ≤ 0.006), GGT level \> 54 IU/L (HR = 1.394, *P* = 0.010) and ALP level \> 112 IU/L (HR = 0.618, *P* = 0.018) were independent predictors of poor survival. Additionally, antitumor local therapy pre-LT was an independent predictor of good survival.

###### 

Multivariate proportional hazard model for overall survival after liver transplantation in 1631 patients with hepatitis B virus-related hepatocellular carcinoma

  **Variables**                          **B**    **SE**   **Wald**   ***P* value**   **OR (95%CI)**
  -------------------------------------- -------- -------- ---------- --------------- ---------------------
  Venous invasion, absent *vs* present   0.893    0.117    57.882     0.000           2.442 (1.940-3.074)
  Pre-LT antitumor therapy                                 7.129      0.032           
  Local therapy                          -0.319   0.138    5.368      0.021           1.375 (1.050-1.801)
  Resection                              -0.227   0.212    1.146      0.284           0.797 (0.526-1.208)
  Age, ≤ 50 *vs* \> 50                   -0.248   0.104    5.655      0.017           0.781 (0.636-0.957)
  ALP, ≤ 112 IU/L *vs* \> 112 IU/L       -0.264   0.111    5.630      0.018           0.768 (0.618-0.955)
  GGT, ≤ 54 IU/L *vs* \> 54 IU/L         0.332    0.128    6.681      0.010           1.394 (1.084-1.793)
  ALT                                                      13.416     0.001           
  ≤ 40 IU/L *vs* 40-80 IU/L              0.340    0.123    7.575      0.006           1.404 (1.103-1.789)
  ≤ 40 IU/L *vs* \> 80 IU/L              0.496    0.141    12.396     0.000           1.642 (1.246-2.164)
  Serum AFP level, in ng/mL                                30.829     0.000           
  \< 200 *vs* 200-400                    0.525    0.185    8.097      0.004           1.691 (1.178-2.427)
  \< 200 *vs* 400-1000                   0.399    0.163    6.012      0.014           1.491 (1.083-2.052)
  \< 200 *vs* 1000-2000                  0.621    0.189    10.804     0.001           1.860 (1.285-2.693)
  \< 200 *vs* \> 2000                    0.725    0.160    20.569     0.000           2.065 (1.509-2.825)
  Number of tumor nodules                                  47.936     0.000           
  Single *vs* 2-3                        0.528    0.138    14.631     0.000           1.695 (1.293-2.221)
  Single *vs* ≥ 4                        0.851    0.124    47.265     0.000           2.342 (1.837-2.984)
  Tumor size, in cm                                        78.643     0.000           
  ≤ 3 *vs* 3-5                           0.152    0.132    1.314      0.252           1.164 (0.898-1.509)
  ≤ 3 *vs* 5-7                           0.739    0.149    24.596     0.000           2.093 (1.563-2.802)
  ≤ 3 *vs* \> 7                          1.252    0.152    67.571     0.000           3.496 (2.594-4.711)
  DM, yes *vs* no                        0.464    0.128    13.230     0.000           1.591 (1.239-2.043)

LT: Liver transplantation; GGT: Gamma-glutamyl transpeptidase; AFP: α-fetoprotein; DM: Diabetes mellitus; ALT: Alanine aminotransferase.

In multivariate Cox modeling for tumor recurrence, the variables analyzed were the same as those used for multivariate analysis for overall survival. The multivariate analysis (Table [6](#T6){ref-type="table"}) indicated that tumor size \> 5 cm (HR = 3.042-4.065, *P* \< 0.001), tumor nodule number ≥ 2 (HR = 1.457-2.144, *P* ≤ 0.009), presence of vascular invasion (HR = 2.182, *P* \< 0.001), AFP level \> 2000 ng/mL (HR = 2.213, *P* \< 0.001), GGT level \> 54 IU/L (HR = 1.433, *P* = 0.006) and TC \>1.7 mmol/L (HR = 1.530, *P* = 0.010) were independent predictors of tumor recurrence post-LT. However, multivariate analysis indicated that DM was not an independent predictor of post-LT tumor recurrence (*P* \> 0.05).

###### 

Multivariate proportional hazard model for tumor recurrence after liver transplantation in 1631 patients with hepatitis B virus-related hepatocellular carcinoma

  **Variables**                          **B**    **SE**   **Wald**   ***P* value**   **OR (95%CI)**
  -------------------------------------- -------- -------- ---------- --------------- ---------------------
  Venous invasion, absent *vs* present   0.780    0.124    39.825     0.000           2.182 (1.712-2.780)
  Pre-LT antitumor therapy                                 11.093     0.005           
  Local therapy                          -0.404   0.138    8.555      0.003           1.498 (1.143-1.964)
  Resection                              -0.285   0.230    1.536      0.215           0.752 (0.480-1.180)
  GGT, ≤ 54 IU/L *vs* \> 54 IU/L         0.360    0.131    7.559      0.006           1.433 (1.109-1.851)
  TC, ≤ 1.7 mmol/L *vs* \> 1.7 mmol/L    0.425    0.165    6.682      0.010           1.530 (1.108-2.113)
  Serum AFP level, in ng/mL                                27.634     0.000           
  \< 200 *vs* 200-400                    0.330    0.198    2.767      0.096           1.391 (0.943-2.051)
  \< 200 *vs* 400-1000                   0.031    0.193    0.026      0.872           1.032 (0.707-1.506)
  \< 200 *vs* 1000-2000                  0.378    0.212    3.161      0.075           1.459 (0.962-2.212)
  \< 200 *vs* \> 2000                    0.794    0.158    25.372     0.000           2.213 (1.625-3.015)
  Number of tumor nodules                                  34.680     0.000           
  Single *vs* 2-3                        0.377    0.144    6.885      0.009           1.457 (1.100-1.931)
  Single *vs* ≥ 4                        0.763    0.130    34.674     0.000           2.144 (1.664-2.764)
  Tumor size, in cm                                        110.647    0.000           
  ≤ 3 *vs* 3-5                           0.143    0.146    0.953      0.329           1.154 (0.866-1.537)
  ≤ 3 *vs* 5-7                           1.112    0.150    55.206     0.000           3.042 (2.268-4.079)
  ≤ 3 *vs* \> 7                          1.402    0.158    78.831     0.000           4.065 (2.983-5.540)

LT: Liver transplantation; GGT: Gamma-glutamyl transpeptidase; AFP: α-fetoprotein.

DISCUSSION
==========

Among the 1631 HCC patients enrolled in this study with HBV-induced cirrhosis who underwent LT in multiple institutions, univariate analysis indicated that patients with DM had worse overall survival rates than patients without DM. There was no significant difference in tumor recurrence-free survival between patients with and without DM. Multivariate analysis also indicated that DM was a significant independent predictor of poor survival, but not of HCC recurrence post-LT. This finding is consistent with previous studies that reported decreased post-operative survival rates in HCC patients with DM\[[@B23],[@B24],[@B29]-[@B32]\].

To our knowledge, only two studies have compared the impact of pre-LT DM on survival and tumor recurrence in HCC patients after LT\[[@B23],[@B24]\]. Connolly et al\[[@B23]\] studied 191 LT-treated HCC patients (12 HBV-related, 104 HCV-related and 81 other HCCs) and determined that the median survival was 78.3 mo for the non-DM patients, but only 31.1 mo for the DM patients. However, no significant differences were observed in survival between the two groups. Siegel et al\[[@B24]\] studied 342 patients with HBV-related HCC (16%) and HCV-related (70%) HCC. They reported that DM patients had worse overall survival than those without diabetes. The reason for the different outcomes in these studies is not clear, but the differences may be partly attributable to the smaller patient populations with HBV-related HCC in the Connolly et al\[[@B23]\] study. Nonetheless, both studies determined that there was no difference in tumor recurrence between DM and non-DM patients. This finding is consistent with the results of the current study.

Additionally, some studies have investigated the post-surgical impact of DM on HBV- and HCV-related HCC patient outcomes\[[@B33]-[@B35]\]. Huo et al\[[@B34]\] showed that DM patients with HBV (but not HCV) had poor long-term outcomes. However, Komura et al\[[@B33]\] reported the opposite results: DM patients with HCV (but not HBV) exhibited poor long-term outcomes. Other studies reported that DM had a similar impact on HCC patients with HBV- and HCV-infection after surgical resection\[[@B35]\]. The reason for these different results is not clear. Our current report is a multi-center study involving a larger number of samples, and we reported that DM had a significant effect on long-term survival post-LT in HBV-related HCC patients, but not on HCC recurrence.

Vascular invasion, tumor size \> 5 cm, and tumor nodule number \> 1 were also demonstrated by the current study to be independent prognostic factors of poor survival. These findings are also consistent with previous studies which reported that vascular invasion, tumor size (≤ 3 cm or ≤ 5 cm, or \> 3 cm) and the number of tumor lesions appears to affect prognosis in DM patients compared with non-DM patients\[[@B23],[@B29],[@B31],[@B33]\]. The current findings suggest that DM may be related to pathological features of tumors that affect long-term survival post-LT in HBV-related HCC patients.

DM, obesity and metabolic syndrome (MS) are related to each other, and are key pathogenetic factors for non-alcoholic fatty liver disease (NAFLD)\[[@B36]\]. It has been reported that "metabolic epidemics" are probably involved in the rise in incidence of HCC, and NAFLD has been cited as the major causative factor\[[@B36]\]. However, although MS has been shown to predispose to NAFLD, and the latter has been associated with an increased incidence of HCC, it has not been shown that MS is a direct etiological factor for development of HCC. While impaired glucose metabolism may be involved in hepato-carcinogenesis, its role in the development of HCC has not been proven\[[@B37],[@B38]\]. In the current study, DM patients with vascular invasion or microsatellite lesions had worse tumor recurrence-free survival rates when compared with non-DM patients. Connolly et al\[[@B23]\] analyzed 191 HCC patients treated with LT, in which 84 (44%) of the patients had DM, and found macrovascular invasion in 20.2% of the DM patients and 9.3% of the non-DM patients. By multivariate analysis, they also found that DM was associated with macrovascular invasion in HCC patients who underwent LT. This supports the current findings that DM may impact the risk of vascular invasion in HCC patients treated with LT.

The current study suggests that DM may be related to older age (\> 50 years) and poor liver function (ALT or AST levels 40-80 IU/L, Child-Pugh score B), which may affect outcomes post-LT. A previous study of 389 patients with HCC and cirrhosis by Ting et al\[[@B31]\] reported that DM, Child-Pugh scores (B and C) and AST levels were significant risk factors affecting HCC prognosis after surgical resection. Huo et al\[[@B32]\] reported that elderly and DM patients were associated with hepatic decompensation. Some previous studies have suggested that DM patients with HCC have an increased cumulative risk of hepatic decompensation after partial hepatectomy\[[@B24]\]. However, unlike partial liver resection, LT offers a more radical oncologic treatment: the complete replacement of a poorly functioning liver with a normal one. Moreover, large doses of hormones and calcineurin inhibitor immunosuppressant drugs (used as anti-rejection therapy post-LT) can increase blood glucose and may induce or aggravate DM or make DM difficult to control. This treatment regimen and its associated side effects may contribute to an elevated incidence of diabetic complications, and decrease survival post-LT for HCC patients with DM (especially among older patients). Thus, we suggest that factors contributing to poor outcomes post-LT in DM patients compared with non-DM patients may include advanced age, reduced liver function and an increase in diabetes-associated complications.

Additionally, the current study observed a survival difference trend between DM and non-DM patients with pre-LT AFP levels \> 2000 ng/mL. The exact cause of this result is not clear. To our knowledge, no previous studies have reported this relationship between DM and elevated serum AFP levels. Some data suggest that hepatocyte damage or regeneration play a role in increasing AFP levels\[[@B39],[@B40]\]. Elevated serum AFP may reflect both HCC progress and the severity of chronic liver damage\[[@B40]-[@B42]\]. Chronic liver disease has been reported to predispose patients to DM\[[@B40],[@B41]\]. In our study, pre-LT DM patients had a higher proportion of Child-Pugh grades B and C, and higher MELD scores compared to non-DM patients. These findings suggest that DM may be related to liver necrosis severity or poor liver function, and that HBV-related HCC patients with both DM and AFP levels \> 2000 ng/mL may have worse survival post-LT.

Several limitations of this study must be considered. First, this study was retrospective. Second, DM was determined based on medical history, fasting glucose, medication use, oral glucose tolerance test results or glycohemoglobin level. However, there was no analysis of glycohemoglobin levels because glycohemoglobin levels were not tested in some pre-LT patients. Third, the HBV DNA assay kits used varied between the hospitals in this study and, therefore, the specific kits used in each institution may have had variable sensitivity and detection limits. However, these results represent a large multi-center sample that suggests that DM is a risk predictor for decreased long-term survival after LT in HBV-related HCC patients.

In conclusion, compared with non-DM patients, DM patients exhibited decreased post-LT survival rates. DM may be associated with various tumor pathological features, older age and poor liver function, and these factors may influence post-LT survival in HBV-related HCC patients. However, no direct relation between DM and HBV infection or HBV load were observed in HCC patients. The current data suggest that DM may affect the long-term post-LT survival of HBV-related HCC patients, but not tumor recurrence. Thus, HBV-related HCC patients with DM undergoing LT should be closely followed to optimize postoperative outcomes. Follow-up examinations are especially important among elderly DM patients, or those who have vascular invasion and AFP levels \> 2000 ng/mL pre-LT. These factors need to be carefully considered when selecting HCC patients for LT. Furthermore, a preventive strategy pre- and post-LT for HCC patients with DM should be established. A future prospective cohort study with larger a sample size should be conducted to confirm these observations.
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